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ABSTRACT
The objective of this study was to assess the prevalence of barriers to interferon treatment in a 
population of HIV/HCV coinfected patients. A cross-sectional study was conducted at two AIDS 
Outpatient Clinics in Brazil. The study included all HIV infected patients followed at these institu-
tions from January 2005 to November 2007. Medical records of 2,024 HIV-infected patients were 
evaluated. The prevalence of anti-HCV positive patients among them was 16.7%. Medical records 
of HCV/HIV coinfected patients were analyzed. 189 patients with the following characteristics were 
included in our study: mean age 43 years; male gender 65%; former IDUs (52%); HCV genotype 
1 (66.4%); HCV genotype 3 (30.5%); median CD4+ T cell count was 340 cells/mm3. Among 189 
patients included in the analyses, only 75 (39.6%) were considered eligible for HCV treatment. The 
most frequent reasons for non-treatment were: non-compliance during clinical follow-up (31.4%), 
advanced HIV disease (21.9%), excessive alcohol consumption or active drug use (18.7%), and psy-
chiatric disorders (10.1%). Conclusions: In Brazil, as in elsewhere, more than half of HIV/HCV 
coinfected patients (60.4%) have been considered not candidates to received anti-HCV treatment. 
The main reasons may be deemed questionable: non-adherence, drug abuse, and psychiatric disease. 
Our results highlight the importance of multidisciplinary teams to optimize the access of coinfected 
patients to HCV treatment.
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INTRODUCTION
Liver disease associated with hepatitis C (HCV) 
is a major problem among HIV-positive indi-
viduals. Different studies in North America and 
Europe have shown that 30% of HIV-infected 
patients are coinfected with hepatitis C virus. 
In Brazil this prevalence ranges from 4.1% to 
53.8% according to different studies.1-10 
In Brazil, the AIDS treatment program guar-
antees free access to highly active antiretroviral 
therapy (HAART) for all people living with 
HIV/AIDS in need of treatment. According to 
recent data, in Brazil around 600,000 individu-
als might be HIV infected.11 Therefore, it would 
be reasonable to think that about 200,000 of 
these patients might be HCV coinfected.
HIV signifi cantly worsens liver disease in 
HCV-positive patients and appears to acceler-
ate progression to cirrhosis. Liver-related mor-
tality is higher in patients infected by both HCV 
and HIV compared to those with HCV alone.12
Successful treatment of HCV with inter-
feron-based therapy reduces the morbidity 
and mortality of patients. Therefore, in HIV 
coinfected patients, treatment of hepatitis C 
should be a priority. Unfortunately, reports 
from different parts of the world have demon-
strated that only 30% of coinfected HIV/HCV 
patients are considered eligible for interferon 
therapy.13-19
In Brazil, there is no data regarding this 
eligibility on coinfected population. In Brazil, 
HIV population is insured by a government-
sponsored health care system that covers treat-
ment for HIV and viral hepatitis coinfections. 
Lack of access to treatment will result in an 
increase in end-stage liver disease with its high 
socioeconomic impact in the future. Strategies 
aimed at improving the eligibility of interfer-
on-based treatment in this population are ur-
gently needed.
The objective of our study was to analyze 
the rate of treatment among HIV/HCV patients 
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followed in two AIDS Outpatient Clinics in Brazil, in order to 
determine the reasons for non-treatment in this group. Our 
goal was to identify specifi c factors that could limit the avail-
ability of HCV treatment in the coinfected population, in or-
der to determine potential opportunities for improving the 
treatment rate in this group.
 
MATERIAL AND METHODS
Study design
A cross-sectional study was conducted at two AIDS Outpa-
tient Clinics in Brazil. The study included all HIV infected 
patients followed at these institutions from January 2005 to 
November 2007. 
Patients and methods
Patient population 
All HIV-infected patients followed at these institutions were 
initially included. 
From January 2005 to November 2007, medical records 
were reviewed to identify anti-HCV reactive patients.
Data collection
A standard collection form was created by the authors of this 
article, in order to optimize the type and means of data col-
lection. The forms were prospectively fi lled out by trained 
physicians who were also responsible for medical care in the 
units. Medical records from these patients were reviewed to 
analyse the demographic and clinical characteristics neces-
sary to fi ll out the collection forms. Data were obtained on: 
age, sex, use of antiretroviral therapy, CD4+ T cell count 
(current), history of exposure to HCV therapy. 
According to the standardized data collection form used 
in the present study, the reasons related to non-treatment 
were as follows: non-compliance during clinical follow-up, 
psychiatric disorders, active drug use, excessive alcohol inges-
tion, other comorbidities (not HIV-related), advanced HIV 
disease, CD4+ T cell count < 200 cells/mm3, advanced liver 
disease, uunfavorable socioeconomic conditions, patient re-
fusal to treatment, patient refusal to liver biopsy, and others.
Eligibility study
In the present study, eligible patients to therapy were de-
fi ned as patients who had indication for HCV therapy and 
were currently on therapy for HCV or had received it in the 
past. Non-eligible patients were defi ned as patients without 
indication for HCV therapy according to clinical practice 
guidelines and patients that despite no absolute contrain-
dication for therapy did not receive it for different reasons 
(according to the standardized data collection form).
In order to better analyze eligibility to treatment, pa-
tients with undetectable HCV-RNA or with no histological 
indication for therapy were not included in the eligibility 
study. We also excluded individuals with missing informa-
tion regarding clinical contraindications for HCV therapy. 
Criteria for treatment were defi ned based upon current 
clinical practice guidelines.
Analyses
A descriptive analysis was performed to tabulate the prima-
ry and contributing factors accounting for why patients did 
not initiate HCV therapy.
 
RESULTS 
The study was conducted at two AIDS Outpatient Clinics in Brazil: 
AIDS Outpatient Clinic, São Bernardo do Campo, São Paulo, Bra-
zil (SBC) and AIDS Outpatient Clinic of Faculdade de Medicina da 
Universidade Federal de São Paulo (UNIFESP). 2024 HIV-infect-
ed patients were evaluated from January 2005 to November 2007. 
The prevalence of anti-HCV positive patients among them was 
16.7 % (Table 1). Plasma HCV RNA levels were measured in 
anti-HCV antibody positive patients. Spontaneous HCV clear-
ance had occurred in 69 (36.5%) anti-HCV antibody positive 
patients.
A total of 340 coinfected patients were identifi ed. One 
hundred eighty-nine patients were included in our study. 
One hundred fi fty-one patients were excluded in our study 
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Table 1. Characteristics of patients (189) in a ret-
rospective study of patients with hepatitis C virus 
(HCV) and HIV coinfection
Age, years, mean (range) 43 (22-75)
Male  121 (65%)
CD4+ cell count, cells/mm3  
Median 394 (20-1490)
Antiretroviral therapy history
yes 166 (88%) 
Risk category for HCV transmission
UDI 98 (%)
HCV Genotype
Genotype 1 113 (66.4%)
Genotype 2 04 (2.3%)
Genotype 3 52 (30.5%)
Genotype 4 01 (0.5%)
Genotype - Data not available 19/189 (10%)
RNA-VHC 
Non-reagent 69 (36.5%)
Liver biopsy available 95 (50.3%)
HIV-HBV-HCV coinfection 13 (6.8%)
*Genotype avaiable for 170 patients.
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for the following reasons: missing clinical data (n = 49), ab-
sence of histological criteria for HCV treatment (n = 22), 
RNA-HCV non-reagent (n = 69), sudden death of unknown 
cause (n = 03), transference of medical unit (n = 8) (Table 3). 
Table 1 summarizes demographic and clinical character-
istics of included patients. The mean age was 43 years (range 
22–75). Most patients were male (65%) and former IDUs 
(52%). Of the total group, 95 (50.3%) patients underwent 
liver biopsy. HCV genotype 1 was the most prevalent geno-
type (66.4%), followed by genotype 3 (30.5%), genotype 2 
(2.3%), and genotype 4 (0.5%).
With regard to HIV infection status, the median CD4+ T 
cell count was 340 cells/mm3 (20-1490). HAART was being 
taken by 88% of patients.
Among 189 patients included in the analyses, only 75 (39.6%) 
of HCV/HIV coinfected patients were considered eligible for 
HCV treatment. They had already been exposed to interferon 
(IFN)-based therapies or were currently under treatment. One 
hundred fourteen patients (72.7%) were considered not eligi-
ble for HCV therapy (Table 2). The reasons for non-treatment 
of this infection were as follows: unfavourable socioeconomic 
conditions (0.5%), waiting for liver biopsy (0.5%), patient refusal 
to liver biopsy (2.2%), patient refusal to treatment (2.2%), other 
comorbidity (5.5%), decompensate cirrhosis (6%), psychiatric 
disorder (10.1%), excessive alcohol consumption or active drug 
use (18.7%), advanced HIV disease or CD4 < 200 cells/mm3 
(21.9%), non-compliance during clinical follow-up (31.4%). 
There were 1.5 reasons for non-treatment per patient (Table 4).
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Table 2. Eligible and non-eligible patients among 189 HIV/HCV coinfected patients
 SBC UNIFESP Total
Eligible patients 43 (43.4%)  32 (35.5%)  75 (39.6%)
Non-eligible patients 56 (56.6%)  58 (64.5%) 114 (72.7%)
Total 99 90 189
Table 3. Reasons for non-inclusion in the eligibility study (151 HIV/HCV coinfected patients)
 SBC UNIFESP Total
 (n) % (n) % (n) %
Missing clinical data 4 45 49 (32.4)
RNA-VHC non-reagent 63 6 69 (45.7)
Minimal hepatic lesions 10 12 22 (14.5)
Sudden death 2 1 03 (02)
Medical unit transference   8 - 08 (5.3)
Total 87 64 151 (100)
Table 4. Reasons for the non-treatment of HCV infection in 114 HIV/HCV coinfected patients
 SBC UNIFESP TOTAL  
Reasons for non-treatment n  n  n  %
Unfavorable socioeconomic conditions 1  - 1 0.5
Waiting for liver biopsy 1  - 1 0.5
Liver biopsy refusal 4  - 4 2.2
Patient refusal to treatment 3 1 4 2.2
Other comorbidity (endocrinologic, neurologic, vascular etc.) 7 3 10 5.5
Decompensated cirrhosis 5 6 11 6.0
Psychiatric disorder 16 4 20 10.1
Excessive alcohol consumption or active drug use 22 12 34 18.7
Advanced HIV disease or CD4 < 200 cells/mm3 20 20 40 21.9
Non-compliance during clinical follow-up  45 12 57 31.4
Total 124 58 182 100
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DISCUSSION
According to our data, only 39.6% of the HIV/HCV coin-
fected patients followed in two Brazilian institutions were 
considered eligible for HCV treatment. The reasons for 
non-treatment of this infection were numerous, with 1.5 
reasons per patient. The most frequent reasons were: non-
compliance during clinical follow-up (31.4%), advanced 
HIV disease or CD4 < 200 cells/mm3 (21.9%), excessive 
alcohol consumption or active drug use (18.7%), and psy-
chiatric disorders (10.1%). Patient refusal to treatment or 
patient refusal to biopsy was occurred in only a minority of 
cases (4.4%).
Several studies have demonstrated comparably low rates 
of treatment uptake in the setting of HIV/HCV coinfection 
in different parts of the world.13-19 Results regarding specifi c 
barriers to treatment were quite similar among those stud-
ies. Psychiatric disorders, excessive alcohol consumption 
and active drug use have frequently been mentioned as im-
portant barriers to treatment among HIV/HCV coinfected 
patients, as well as among HCV mono-infected patient.20-24 
Depression is one of the most frequent diagnoses among 
all psychiatric disorders in HCV mono and coinfected pa-
tients. In the HIV coinfected population, it has been associ-
ated with decreased adherence to medical therapy25 and in-
creased mortality.26,27 Our study is consistent with these data. 
Among our group of coinfected patients, severe psychiatric 
disorders, mainly severe depression, non-compliance to 
therapy, and advanced HIV disease were strongly associated 
with non-eligibility to HCV treatment.
Considering that HIV coinfection is currently an exclu-
sion criteria at almost all transplant centers, there may be 
more than an urgency to treat these patients. Efforts to im-
prove the rate of treatment in the coinfection group must 
accompany the improvements being realized in available 
treatment of chronic hepatitis C. Recognition that HIV-
infected patients who also have hepatitis C may be prone 
to more depressive symptoms has important management 
implications. Institution of antidepressant therapy may 
enhance medical adherence, which is the key to successful 
antiretroviral management and patient’s ability to tolerate 
treatment for HCV infection.
Individuals who are not currently eligible to receive 
HCV treatment should be referred to management of co-
morbid conditions and re-evaluated at regular intervals to 
determine if these barriers have been overcome (e.g., suc-
cessful treatment of depression). Ideally, a multidisciplinary 
team including experts in addiction medicine, psychologists, 
and psychiatrics should take care of these patients. Physi-
cians must carefully weigh the potential benefi ts and risks 
of therapy for each individual, taking into account the best 
predictor of treatment response.
It would be important to emphasize that in our opinion 
not all HCV/HIV coinfected patients are adequate candidates 
for HCV therapy. The need for treatment mainly relies on the 
severity of liver damage, the virological characteristics of HCV 
infection (genotype, viral load), and the HIV status. Different 
contraindications for HCV therapy, however, may discourage 
its use (i.e., severe neuropsychiatric conditions etc.).
In patients with CD4 counts below 200 cells/mm3, the 
decision to treat HCV infection must be made cautiously. 
In this group of patients, HCV therapy should be deferred, 
mainly due to concerns on toxicity since the response may 
be much poorer. Individuals with prior history of serious 
neuropsychiatric disorders should not be treated, because 
interferon can exacerbate these conditions. Patients current-
ly engaged in heavy alcohol intake or illegal drug addiction 
practices should delay treatment, whereas all efforts should 
be devoted to put them into detoxifi cation programs.
Successful treatment and virus eradication with inter-
feron-based therapy can potentially reduce the morbidity 
and mortality associated with the development of cirrhosis 
from hepatitis C. Solving the problems of poor adherence 
to medical visits, and active alcohol and drug abuse, could 
ultimately result in the treatment of HCV in many coin-
fected patients.
Our study had some limitations. First, the information 
about reasons for non-treatment was collected from medical 
charts that may vary in completeness and be more vulner-
able to bias. An attempt was made to minimize complete-
ness bias by applying the same standardized questionnaire 
to all cases included. Second, this study was largely derived 
from two urban centers. Therefore it may be less generalized 
to other populations in Brazil. Third, treatment eligibility 
is likely to vary over time so that treatment-ineligible per-
sons may become eligible as their clinical and social circum-
stances change. Re-evaluations at regular intervals of the 
same patient population could better determine these barri-
ers. Fourth, unfavorable socioeconomic conditions may not 
have been fully evaluated, since all information came from 
medical charts. In order to minimize this kind of bias, the 
physician in charge of each patient was invited to complete 
the standardized collection form to all cases included.
Despite these limitations, we believe that our results 
demonstrate that coinfection treatment requires expertise 
in managing addictions, psychiatric illness, and poverty. 
Like many other services in the world, Brazil’s AIDS and 
hepatitis treatment programs have very limited access to 
these services.
According to our data, 31.4% of the subjects involved in 
our study were not referred to treatment because they were 
non-adherent to HIV treatment and were non-compliant 
during clinical follow-up. We understand that one way to 
achieve a more signifi cant number of coinfected patients 
under HCV treatment is to optimize adherence in HIV pro-
grams. To achieve success with currently available therapies, 
a multidisciplinary clinical care model is necessary. 
Treatment of hepatitis C in HIV/HCV coinfected in Brazil
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A multidisciplinary model of care could address the so-
cial and psychiatric issues frequently encountered in this 
population, reduce the loss of patients to follow-up, effec-
tively educate and prepare patients, and treat a larger pro-
portion of the HIV/HCV coinfected population. 
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